Dr. Petri Bono Appointed CMO of Faron Pharmaceuticals

Dr. Petri Bono will take over as Chief Medical Officer (CMO) of Faron Pharmaceuticals on August 15. Dr. Bono formerly worked at Terveystalo, the biggest private healthcare provider in Finland, as the Chief Medical Officer and a member of the Group Executive Team. He has served in a number of executive capacities at Helsinki University Hospital, most notably as the Comprehensive Cancer Center's Director and Chief Physician. Dr. Bono has published 102 peer-reviewed articles in international publications and taken part in various cancer studies ranging from Phase 1 to Phase 3, including early phase immuno-oncological investigations.

Because of his expertise in molecular and immunological oncology, Dr. Bono is ideally equipped to assist Faron's immuno-oncology program, which employs cutting-edge immunotherapies that target myeloid cells to treat cancer. He is eager to advance Faron's cutting-edge immunotherapy work and establish bexmarilimab as a mainstay of cancer treatment going forward. Dr. Juho Jalkanen, CEO of Faron, is thrilled to have such a capable and driven oncologist join the team as the new CMO.

Acting CMO Dr. Birge Berns, seconded from tranScrip Ltd., will remain part of the medical leadership team working on bexmarilimab development. Dr. Berns has been instrumental in helping Faron achieve success with the FDA and build Bexmarilimab to its current state.